4-HO-MPT

Last updated
4-HO-MPT
4-HO-MPT.svg
Names
Preferred IUPAC name
3-{2-[Methyl(propyl)amino]ethyl}-1H-indol-4-ol
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C14H20N2O/c1-3-8-16(2)9-7-11-10-15-12-5-4-6-13(17)14(11)12/h4-6,10,15,17H,3,7-9H2,1-2H3 Yes check.svgY
    Key: XFQDDPQGBLSNCN-UHFFFAOYSA-N Yes check.svgY
  • InChI=1S/C14H20N2O/c1-3-8-16(2)9-7-11-10-15-12-5-4-6-13(17)14(11)12/h4-6,10,15,17H,3,7-9H2,1-2H3
    Key: XFQDDPQGBLSNCN-UHFFFAOYAC
  • OC1=CC=CC2=C1C(CCN(C)CCC)=CN2
Properties
C14H20N2O
Molar mass 232.327 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

4-Hydroxy-N-methyl-N-propyltryptamine, commonly known as 4-HO-MPT or meprocin, is a psychedelic drug in the tryptamine class of chemical compounds and is a higher homologue of the naturally occurring substituted tryptamine psilocin as well as being the 4-hydroxyl analog of MPT.

Contents

History

4-HO-MPT was first synthesized and bioassayed by biochemist Alexander Shulgin and written about in his 1994 book TiHKAL . [1]

Effects and dosage

For psychedelic effects, the dosage and duration are listed as "unknown" in TiHKAL. [1] In more recent literature, the dosage has been reported to be 20 to 30 mg orally. [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MPT. In a single trial of 8 mg orally of 4-HO-MPT HCl from TiHKAL, it is described as producing visual distortion, vertigo, and slight insomnia. [1]

4-HO-MPT is not scheduled by the United Nations' Convention on Psychotropic Substances. [3]

United States

4-HO-MPT is not scheduled at the federal level in the United States, [4] but it is possible that 4-HO-MPT could legally be considered an analog of psilocin, in which case, sales or possession with intent for human consumption could potentially be prosecuted under the Federal Analogue Act. [5]

References

  1. 1 2 3 4-HO-MPT Entry in TIHKAL @ Erowid.org
  2. ↑ Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species" (PDF). Neuropharmacology. 167 107933. doi:10.1016/j.neuropharm.2019.107933. PMC   9191653 . PMID   31917152. Table 4 Human potency data for selected hallucinogens. [...]
  3. ↑ "Convention on Psychotropic Substances, 1971". Archived from the original on 2022-01-19. Retrieved 2016-06-10.
  4. ↑ "§1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2016-06-10.
  5. ↑ Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.